Vaccines R&D & Vaccination

Pr. Didier BETBEDER has 25 years’ experience in drug delivery using colloids, ranging from basic research to clinical studies. Working with the World Health Organisation he obtained his PhD in 1988 on drug targeting to treat sleeping sickness, before spending 2 years as a post-doctoral fellow at the University of Warwick (England). He was then engaged by BioEurope, a company specialising in biocatalysis, before joining Biovector Therapeutics (France) as Research director from 1992 – 2001. He is Professor at the University of Artois and Lille 2 since 2001.

He developed from research to clinical development a technology based on polysaccharide nanoparticles. He conducted 5 clinical trials. Nasal flu vaccine formulations have been clinically trailed with BioChem Pharma (Canada),and SmithKline Beecham (Belgium). His researches are focusing on studying the mechanisms implied in nanoparticles interactions within mucosa. He has extensive experience in Nanomedicine, over 110 international publications and 23 patents to his name. He is the founder of VAXINANO a company who is developing vaccines for human and animal health (www.vaxinano.com)

Richard T Wyatt, Ph.D. received his Doctorate in Immunology from Tufts University School of Medicine at the Sackler School of Graduate Biomedical Sciences in Boston, MA. Currently Dr. Wyatt is a Professor in Immunology in the Department of Immunology and Microbiology at the Scripps Research Institute. He served on the editorial board of the Journal of Virology, Frontiers in Immunology and Vaccines. He is a member of the Scripps CHAVI-ID, the Bill and Melinda Gates Foundation CAVD, the UCSD CFAR Grant Review Committee, is a member of the AmfAR American Foundation for AIDS Research Cure Working Group and the American Association for the Advancement of Science. He has co-authored over 160 peer-reviewed articles, predominantly focused on the HIV-1 envelope glycoproteins (Env) as antigens and immunogens. Dr. Wyatt was formerly a Senior Investigator and Chief of the Structural Immunology Section at the Vaccine Research Center at the NIH in Bethesda, MD and is a charter member of IAVI’s Neutralizing Antibody Consortium. And has been listed on the Thomson-Reuters World’s Most Influential Scientific Minds and Highly Cited Researchers. Dr. Wyatt’s research focuses on the structure, function and especially the immunogenicity of the HIV-1 Env, the only virally encoded proteins on the surface of the virus. Because many viral vaccines protect against disease by the elicitation of neutralizing antibodies.

Dr. Wyatt’s lab studies engineered HIV-1 Env trimers as candidate vaccine immunogens and at the atomic level of structural resolution to gain insight in how to better elicit antibodies directed against these variable, heavily glycosylated neutralizing determinants. His lab generates a diverse array of well-ordered, homogeneous trimers to elicit HIV broadly neutralizing antibodies (bNAbs) to date only elicited during natural HIV infection. Recently, Dr. Wyatt’s laboratory is exploring interactions of particulate immunogens with B cells to learn rules of immunogenicity to forward HIV -1 vaccine development and is also using bNAbs in focused curative modalities.

Dr. Patel is the Senior Director of Product Development at Emergent Biosolutions (USA). He is responsible for developing oral and injectabledelivery platforms and process for vaccines. He has developed process, formulation and delivery system for small molecules, DNA vaccines, Virus Like Particle vaccines (VLP), cell therapy, Adenovirus and Bacterial vaccines from development to GMP manufacturing.

Dr. Patel CMC experience ranges from pre-clinical to life cycle management with successful track record of commercialization of the biologics. He has been an integral part of the QA, QC and GMP manufacturing teams where he has developed over 15 clinical products and trained theGMP staff on the production technology. Prior to PaxVax, Dr. Patel worked as a Senior Scientist II, doing Formulation Research at NexBio Inc. and as a Sr. Scientist at MicroIslet, Inc where his primary responsibilities involved developing process and formulations for encapsulating cells (islets) for in vivotransplantation. Dr. Patel received his Ph.D. and M.S. in Chemical Engineering with special interest in Nanotechnology field, from Louisiana Tech University, and, B.S. Chemical Engineering from University of Poona (India)

Dr. Ruan is the Sr. Director of process development and production at Emergent Biosolutions (USA). She has extensive experience in bioprocess development from preclinical to licensure. She has a Ph.D. degree in biochemical engineering from South China University of Science and Technology.

She managed Process development, clinical production (Phase I, Phase II, and Phase III), facilities, materials management, validation, Tech Transfer and CMO. Dr. Ruan is responsible for developing and manufacturing oral delivery vectors and injectable virus-like-particles for vaccines, as well as researching, evaluating, and optimizing new technology platforms to improve the production scale and stability of the products.

Ayoub Bazzaz has completed his PhD at the age of 30 years from Nottingham University, UK and continued postdoctoral research works for over 10 years at Leeds, Liverpool and Cardiff Universities in UK.

He is one of the founder of Faculty of Medicine of Tikrit University, Iraq and first head of Anatomy department 1988-1991. Has supervised and refereed many PhD and MSc students in Iraq, KSA, Libya and UK and has over 60 published scientific papers in reputed International journals.

Brian G. Hubka is the CEO of Contamination Prevention Technologies, Inc. This company provides a vast array of contamination remediation and prevention technologies and products to eliminate and prevent mold, bacteria, viruses, prions and the like. They are also specialists in biofilm remediation and elimination.

. He also consults on contamination issues in pharmaceutical and biotechnology companies. Has worked with Pfizer, Amgen, Celgene and many others. He is a graduate of University of Notre Dame pre-medicine. He is also a frequent speaker and has authored book chapters for many PDA/DHI books.

Jeanne Moldenhauer, Vice-President of Excellent Pharma Consulting has more than 30 years’ experience in the pharmaceutical industry.

She chaired the Environmental Monitoring/Microbiology Interest Group of PDA for more than 15 years, served on the Scientific Advisory Board of PDA for 20 years, founded the Rapid Microbiology User’s Group™, and is a Member of ASQ and RAPS. She is the author of many books and numerous publications (book chapters and magazine articles)

Leandro Resende has completed his PhD at the age of 38 years from Paulista State University, Botucatu – SP, Brazil. He is currently the technical responsible for the oncology gynaecology department of the Base Hospital of the Federal District in Brasília – DF, Brazil.

He has published articles with an emphasis on oncology gynaecology and lectures at international congresses about the HPV vaccination program in Brazil.

Kubar Olga, MD, PhD is the Leading Researcher in the Laboratory of Etiology and Control of Viral Infections in St.Petersburg Pasteur Institute. During many years Olga Kubar is responsible for the research connected with the study ethical aspects of infectious diseases and vaccination. As ex-member of IBC UNESCO she took part in developing of the several international documents on bioethics. She is the Board-member of EFGCP responsable for education and the member of Russian National Committee on Bioethics in UNESCO Commision of Russia.

She published more than 100 papers in reputed journals and 9 Books on Bioethics and Infectious Diseases.

Geert Vanden Bossche received his doctoral degree in Veterinary Medicine from the University of Ghent, Belgium, and obtained his PhD degree in Virology from the University of Hohenheim, Germany. Following his postdoctoral training in Equine Medicine and Surgery at the Free University of Berlin, Dr. Vanden Bossche went on to complete additional training in Virology, Immunology and Molecular Biology at the Robert Koch Institute in Berlin where he became board certified in Virology and Microbiology. Geert then transitioned to Environmental Virology and joined the University of Hohenheim as Head of the Virology research lab where he conducted several research projects related to the detection of microbial contamination in environmental samples and biophysical behavior of viruses in aqueous environments.

Dr. Vanden Bossche was given the venia legendi in Virology (1996) and held adjunct faculty appointments from the University of Hohenheim and the European Faculty for Environmental Sanitation where he taught Zoonotic Diseases and Environmental Virology. After his career in Academia, Geert joined GlaxoSmithKline to serve various roles in early and late vaccine development and as Head of GSK’s Vaccine Adjuvant and Alternative Vaccine Delivery platform. After leaving GSK, Geert joined Novartis Vaccines & Diagnostics in Siena (Italy) and Emeryville (US) where he served as director on the RSV and Influenza vaccine project and as Head of Adjuvants. Following his engagement with Novartis, Geert served as Global Project Director in Solvay Biologicals’ Influenza program devoting his primary efforts to coordinating the early stage development of an improved seasonal and pandemic Influenza cell-culture vaccine. He then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle, US. In his role as Senior Program Officer, Geert has been initiating and coordinating numerous efforts supporting the innovation needed to develop new vaccines and new approaches to immune intervention. Geert also worked with GAVI, where he has been tracking efforts to develop an Ebola vaccine. He has represented GAVI in fora with other partners, including WHO and CDC, to review progress on the fight against Ebola and to build plans for a global pandemic preparedness. More recently, Geert joined the German Center for Infection Research (DZIF) where he has been coordinating R&D projects related to vaccines and infectious diseases at German universities and research centers. Geert’s research activities are now centered on the design and development of NK cell-based vaccines. He is the author of more than 20 scientific papers and has been invited to speak at multiple international congresses.

Dr. Cheepsattayakorn graduated Doctor of Medicine from Chiang Mai Medical School, Chiang Mai University, Chiang Mai, Thailand in 1986. He then further had trained in Internal Medicine, Pulmonology, and Radiology at Chiang Mai University Medical School. He graduated numerous Fellowships in Respiratory Medicine from the Royal Colleges of Physicians of London, Edinburgh and Thailand, Royal College of Physicians and Surgeons of Glasgow, American College of Physicians, and American College of Chest Physicians. Presently, he serves both Editor and Editorial Board Member and also referee of several international journals. He has very high experience in the fields of Pulmonary Diseases and Tuberculosis including Infectious Diseases and Immunology. He has numerous scientific publications, more than 130 publications both in national and international journals and books.

1.) Novel Therapeutics in Lung Cancer 2.) Nontuberculous mycobacterial infection in HIV- infected patients 3.) Multidrug – resistant tuberculosis patterns in HIV- infected patients 4.) Chemokine gene polymorphisms and their susceptibility to tuberculosis 5.) Breath Tests in Respiratory and Critical Care Medicine 6.) Tropical Infectious Diseases 7.) Human Genetics and Infectious Diseases 8.) Environmental and Occupational Pulmonary Diseases

I am a microbiologist with a long-term interest in better understanding the pathogenesis of emerging infectious diseases. I received my veterinary and master’ degrees from Cairo University, Egypt and a Ph.D. from the School of Medicine University of Maryland At Baltimore, USA. Currently, I am a professor of microbiology at the University of Wisconsin-Madison. My research involves developing new technologies and innovative approaches to understand bacterial pathogenesis and to generate useful therapies (drugs and vaccines).

Currently, we are working on the functional genomics of Mycobacterium tuberculosis and M. avium subsp. paratuberculosis. Recently, we started to utilize nanotechnology to develop nano-biosensors and Nanovaccines to control animal infections, including avian viral agents. In 2011, I started a biotechnology company (Pan Genome Systems, INC.) to further develop intellectual properties generated by our group (vaccine-based patents) into products useful to improve human and animal health. During the past decade, I have mentored 17 undergraduates, 19 graduate students and 10 post-doctoral fellows in my laboratory at the University of Wisconsin-Madison. The results of my career at UW-Madison were shared through more than 50 articles in peer-reviewed journals.